VIP may push renal cancer cells toward autophagy and cell death (preclinical)

A 2026 preclinical paper reports vasoactive intestinal peptide (VIP) can induce autophagy and cytotoxicity in renal cell carcinoma models, with a proposed SIRT3-dependent mechanism. Interesting biology, far from a therapy.